A game-changer for obesity and heart failure? Dr Pandey reveals breakthrough GLP-1 trial results that show reduced cardiovascular risk and better outcomes for HFpEF patients. Don’t miss this!

Weight-inclusive health care is the provision of equitable care without perpetuating weight stigma among patients of all body ...

Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.

Liraglutide, a GLP-1 significantly lowers the rate of recurrent stroke in patients with diabetes, with no apparent increase ...

It’s obvious these drugs are trimming waistlines across the nation; what may be less obvious is that they might also reshape ...

The overgrown foliage had been hiding an ancient structure. Archaeologists identified the ruins as a pyramid-like building dating back at least 3,800 years, officials said. It has three ...

Background: Despite their potential, Glucagon-like peptide-1 receptor agonists (GLP-1 RA) have not been well studied in cardiac amyloidosis (CA) as randomized trials on GLP-1 RA have excluded patients ...

Semaglutide mimics the action of the natural protein glucagon-like peptide ... meaning its molecules mimic the structure of GLP-1, binding to its receptor like a counterfeit key someone’s ...

Researchers from the Institute of Science Tokyo and Osaka Medical and Pharmaceutical University said that they have developed a peptide that can bind to the spike proteins of SARS-CoV-2 to prevent ...

Lipidated analogues of glucagon-like peptide 1 (GLP-1) have gained enormous attention as long ... This work provides a systematic study of the solubility, structure, oligomerization, and long-term ...